Floatz logo

Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells

Recurrent Chronic Lymphocytic Leukemia

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

72 Active assets in the Recurrent Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Humax-Cd20
Emory University
Phase 4BBB
Acalabrutinib
Zulfa Omer
Phase 4BBB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
CD19 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
CD22 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →